Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease
Status unconfirmed
Conditions studied: Fabry Disease
In brief
The purpose of this research is to collect biological samples (urine) to develop assays for immune biomarkers to possibly in the future be able to screen subjects with Fabry disease and be able to understand better progression of nephropathy in Fabry disease and predict nephropathy in Fabry disease.
Key facts
- Study ID
- NCT06065605
- Run by
- Lysosomal and Rare Disorders Research and Treatment Center, Inc.
- People needed
- 40
- Starts
- 2023-09-14
- Expected to finish
- 2025-09-12
- Last updated by the study team
- 2023-10-04
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Male and Female subject is greater than 18 but not older than 80 years.
- Subject willing to sign the informed consent and/or assent.
- Confirmed diagnosis of Fabry disease based on deficient α-Gal A enzymatic activity and molecular analysis demonstrating pathogenic variants in the GLA gene.
You may not qualify if…
- Any other known genetic condition associated with CKD.
- Evidence of hepatitis B or C infections or other chronic infectious diseases,
- Pregnancy or breastfeeding.
- Any other chronic condition, as per PI's discretion, that makes the subject ineligible.
Where it is running
- Lysosomal & Rare Disorders Research & Treatment Center — Rockville, Maryland, United States (enrolling)
- Lysosomal & Rare Disorders Research & Treatment Center — Fairfax, Virginia, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.